Does erythropoietin have a role in the treatment of β-hemoglobinopathies?

Abstract

This review presents the indications and contraindications (pros and cons) for the potential use of erythropoietin (Epo) as a treatment in β-thalassemia and sickle cell anemia (SCA). Its high cost and route of administration (by injection) are obvious obstacles, especially in underdeveloped countries, where thalassemia is prevalent. We believe that from the… (More)
DOI: 10.1016/j.hoc.2013.11.002

Topics

  • Presentations referencing similar topics